Deferasirox

Evidence Level: L4

Predicted Indications: 10

Deferasirox
Deferasirox: From Transfusional Iron Overload in Beta-Thalassemia to HIV Infectious Disease

## Pharmacist Assessment Report

Deferasirox: From Transfusional Iron Overload in Beta-Thalassemia to HIV Infectious Disease

One-Sentence Summary

Deferasirox is an oral iron chelator, originally associated with beta-thalassemia and related hemoglobinopathies. The TxGNN model predicts it may be effective for HIV infectious disease, but there are currently 0 clinical trials and only 2 publications (one general drug overview and one preclinical study), so this remains a research question rather than an established direction.

Quick Overview

Item	Content
Original Indication	Beta-thalassemia and related hemoglobinopathies (from knowledge-graph indication data; the Singapore license records contain no indication text)
Predicted New Indication	HIV infectious disease
TxGNN Prediction Score	99.40%
Evidence Level	L4
Singapore Market Status	✓ Marketed
Number of Registrations	6
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, deferasirox is an iron chelator, its use in iron overload from beta-thalassemia and other hemoglobinopathies is established, and mechanistically it may be applicable to conditions in which iron status influences disease biology.

The proposed link to HIV is indirect. A 2021 preclinical study (PMID 34550543) reports that iron in endolysosomes restricts Tat-mediated HIV-1 LTR transactivation by increasing Tat oligomerization and β-catenin expression. This suggests that iron chelation could modulate HIV-1 transcription. However, the direction of the effect is unresolved: depleting iron may relieve the restriction and increase Tat activity, which would work against the drug.

The other linked paper (PMID 16529348) is a general new-drug overview with no HIV-specific data. The high model score is therefore not backed by clinical evidence.

Other predictions in the list

Nine further predictions were generated. All are graded L4 or L5, and none has a clinical trial.

Predicted Indication	Score	Evidence Level	Comment
Chronic hepatitis C virus infection	99.39%	L4	Iron accumulation is common in chronic HCV, but the only linked paper is a ferritin measurement method study
Neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter	99.23%	L5	No mechanistic link or evidence
Obsolete familial combined hyperlipidemia	99.20%	L5	Obsolete disease term, likely an ontology artifact
Dermatofibrosarcoma protuberans	99.11%	L5	No documented link to iron chelation
Simian immunodeficiency virus infection	98.96%	L5	Likely propagated from the HIV association
Feline acquired immunodeficiency syndrome	98.96%	L5	Veterinary disease, likely propagated from the HIV association
Beta-thalassemia with other manifestations	98.59%	L5	Likely a variant of an existing indication, not true repurposing
Hereditary pyropoikilocytosis	98.55%	L5	Plausible indirect rationale via iron overload from chronic hemolysis
Pyruvate kinase deficiency of red cells	98.50%	L5	Iron overload is a recognized concern, and a targeted literature search would be a reasonable next step

Literature Evidence

PMID	Year	Type	Journal	Key Findings
34550543	2021	Preclinical/In vitro study	Journal of Neurovirology	Endolysosomal iron restricts Tat-mediated HIV-1 LTR transactivation by increasing Tat oligomerization and β-catenin expression
16529348	2006	Review	Journal of the American Pharmacists Association	General overview of new drugs, including deferasirox; no HIV-specific data

No clinical trials are registered for this indication.

Singapore Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
SIN15213P	Jadenu Film Coated Tablet 90 mg	Film-coated tablet	Not stated in the licence record
SIN15215P	Jadenu Film Coated Tablet 360 mg	Film-coated tablet	Not stated in the licence record
SIN17174P	Desroxia Film-Coated Tablets 90 mg	Film-coated tablet	Not stated in the licence record
SIN17173P	Desroxia Film-Coated Tablets 360 mg	Film-coated tablet	Not stated in the licence record
SIN17088P	Ferasiro Film Coated Tablet 90 mg	Film-coated tablet	Not stated in the licence record

A sixth licence, SIN17087P (Ferasiro 360 mg), is also valid. All six licences are single-ingredient oral products.

Safety Considerations

Conditions flagged in the knowledge graph (not label text): liver failure, liver disease, cirrhosis, kidney disease and impaired renal function, thrombocytopenia, neutropenia and agranulocytosis (including several congenital neutropenia syndromes), anemia, hyperbilirubinemia and Gilbert syndrome, gallbladder disease, active peptic ulcer disease, ocular hypertension, multiple organ dysfunction syndrome, and cancer.
Drug Interactions: 100 interactions were identified. Major-level examples include:
- Corticosteroids (hydrocortisone, dexamethasone, betamethasone, triamcinolone)
- Amphotericin B (including lipid complex, cholesteryl sulfate and liposomal forms)
- Aspirin
- Mesalazine and balsalazide
Moderate-level examples include rabeprazole, pioglitazone, alosetron, aprepitant, clarithromycin, saxagliptin, aluminum hydroxide, cisapride and dexfenfluramine.

Please refer to the package insert for label warnings and contraindications. The package insert was not available for this review.

Conclusion and Next Steps

Decision: Hold

Rationale: The HIV prediction rests on one indirect preclinical study whose direction of effect is unclear, and no clinical trials exist. The model score alone does not justify moving forward.

To proceed, the following is needed:

Obtain the Singapore package insert (HSA) to confirm approved indications, warnings and contraindications
Obtain mechanism of action data from DrugBank
Clarify in vitro whether iron chelation by deferasirox suppresses or enhances HIV-1 Tat activity
Assess the safety concerns above (kidney, liver, and blood cell counts) for people living with HIV
Run a targeted literature search for chelation in pyruvate kinase deficiency, the most mechanistically plausible alternative prediction, and check whether "beta-thalassemia with other manifestations" is only a variant of an existing indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.